SYRE | Ticker Profile - Titan Protect

SYRE

Spyre Therapeutics, Inc.

Healthcare · Biotechnology · NMS

$73.65

Data: 2026-05-28

✗ ETHICAL FAIL

Unknown MOAT

MODERATE

Data Confidence: 71.4%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$6.3B

Total market value of the company

Trailing P/E

N/A

Forward P/E

-24.10

Based on estimated future earnings — lower means cheaper

Rev Growth

N/A

Year-over-year revenue change

Profit Margin

0.0%

How much profit the company keeps from each dollar of revenue

ROE

-31.1%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$95.00

+29% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 15 analysts covering this stock

About Spyre Therapeutics, Inc.

Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A). It is also developing SPY003, a clinical-stage program, which is in phase-2 clinical stage designed to bind to interleukin 23 (IL-23); SPY120, a combination of anti-a4ß7 and anti-TL1A mAbs; SPY130, a combination anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. The company was incorporated in 2013 and is based in Waltham, Massachusetts.

https://www.spyre.com

Country: United States Employees: 112 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% N/A

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

ACCUMULATION

Smart money appears to be building positions quietly

Sharpe Ratio

0.934

Good returns relative to risk taken

Kelly Fraction

0.0742

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

0.717

Acceptable balance between returns and drawdown risk

Annual Return

50.3%

Historical annualised return based on price data

Max Drawdown

-70.2%

Largest peak-to-trough decline — the worst it has been

HMM State

CRISIS

Elevated risk detected — extreme caution warranted

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

3.13

Significantly more volatile than the market

52W High

$78.80

7% below the year high

52W Low

$13.93

429% above the year low

Avg Volume

1,102,832

Average daily shares traded — higher means easier to buy and sell

Short Ratio

9.2

Days it would take all short sellers to cover — higher means more crowded

Short % Float

15.3%

Elevated short interest — bears are positioned against this

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-2.12

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

N/A

Current Ratio

8.97

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

8.80

Like current ratio but excludes inventory — stricter test

Gross Margin

0.0%

Revenue left after cost of goods — higher means pricing power

Operating Margin

0.0%

Profit from core operations before interest and tax

Free Cash Flow

$-75,515,504

Negative — the business is spending more than it generates

Revenue (TTM)

N/A

Total revenue over the last 12 months

Net Income

$-148,703,008

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$115.00

Target Median

$95.00

Target Low

$78.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go